Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
Annual operating results turned negative, while the two largest contract manufacturing customers represented approximately 90% of fiscal 2026 revenue.
Rhea-AI Summary
Integrated BioPharma (INBP) reported results for the fiscal year ended June 30, 2026, with revenue of $43.9 million.
Annual revenue fell 19.3% from $54.4 million in fiscal 2025. Gross profit declined to $0.8 million from $5.6 million. The company recorded a $2.7 million operating loss after $2.0 million of operating income a year earlier. Its annual net result shifted to a $2.8 million loss, or $0.09 per share, from $0.8 million of income, or $0.03 per share.
For the quarter ended June 30, 2026, revenue fell 31.0% to $9.8 million from $14.2 million a year earlier. The quarterly operating loss was $0.9 million, compared with $0.6 million of operating income. Revenue from the two largest customers in the contract manufacturing segment represented approximately 90% of total fiscal 2026 revenue, versus approximately 84% in fiscal 2025.
Positive
- None.
Negative
- Fiscal 2026 revenue fell 19.3% to $43.9 million
- June-quarter revenue fell 31.0% to $9.8 million
- Annual gross profit fell to $0.8 million from $5.6 million
- Annual operating result shifted to a $2.7 million loss
- Annual net result shifted to a $2.8 million loss
- Two largest contract manufacturing customers represented approximately 90% of fiscal 2026 revenue
AI-generated analysis. How Rhea-AI works. Not financial advice.
HILLSIDE, NJ / ACCESS Newswire / September 25, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026.
Revenue for the quarter ended June 30, 2026 was
Revenues for the fiscal year ended June 30, 2026 were
For the quarters ended June 30, 2026 and 2025, the Company had a net loss of approximately
For the fiscal year ended June 30, 2026, the Company had a net loss of approximately
"Our revenue decreased by approximately
A summary of our financial results for the three months and fiscal years ended June 30, 2026 and 2025 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended | Fiscal Year Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Total revenue | $ | 9,796 | $ | 14,175 | $ | 43,872 | $ | 54,353 | ||||||||
Cost of sales | 9,768 | 12,706 | 43,072 | 48,791 | ||||||||||||
Gross profit | 28 | 1,469 | 800 | 5,562 | ||||||||||||
Selling and administrative expenses | 897 | 880 | 3,505 | 3,542 | ||||||||||||
Operating (loss) income | (869 | ) | 589 | (2,705 | ) | 2,020 | ||||||||||
Other income, net | 19 | 6 | 142 | 42 | ||||||||||||
(Loss) income before income taxes | (850 | ) | 595 | (2,563 | ) | 2,062 | ||||||||||
Income tax expense, net | 516 | 773 | 279 | 1,254 | ||||||||||||
Net (loss) income | $ | (1,366 | ) | $ | (178 | ) | $ | (2,842 | ) | $ | 808 | |||||
Net (loss) income per common share: | ||||||||||||||||
Basic | $ | (0.04 | ) | $ | (0.01 | ) | $ | (0.09 | ) | $ | 0.03 | |||||
Diluted | $ | (0.04 | ) | $ | (0.01 | ) | $ | (0.09 | ) | $ | 0.03 | |||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 31,059,610 | 30,622,045 | 31,059,610 | 30,295,655 | ||||||||||||
Diluted | 31,059,610 | 30,622,045 | 31,059,610 | 31,168,372 | ||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact:
Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Integrated BioPharma perform in fiscal 2026?
Integrated BioPharma reported $43.9 million in revenue for the fiscal year ended June 30, 2026, down 19.3% from $54.4 million in fiscal 2025. Its net result was a $2.8 million loss, or $0.09 per share, compared with $0.8 million of income, or $0.03 per share, a year earlier.
What were Integrated BioPharma's results for the quarter ended June 30, 2026?
Revenue for the quarter ended June 30, 2026, was $9.8 million, down 31.0% from $14.2 million a year earlier. The company recorded a $1.4 million net loss, or $0.04 per share, compared with a $0.2 million net loss, or $0.01 per share, in the prior-year quarter.